The Health Pulse S3E1: The (Not So) Secret to Making Cancer Care More Equitable and Effective
Dr. Sean Khozin is on a mission to break down silos and improve access to quality cancer care for all. Khozin is a board-certified oncologist, physician scientist, data scientist and the CEO of ASCO’s CancerLinQ, a nonprofit health technology company focused on improving health outcomes for all patients with cancer. On this episode of The Health Pulse, Khozin joins host Alex Maiersperger to discuss how his organization is democratizing access to the best cancer care by bringing real-world evidence based tools to the point of care. As Khozin explains, only about 5% of cancer patients can access clinical trials. This means in oncology, clinical trial data often lacks external validity because it represents highly selective patient populations. CancerLinQ helps close the gap using real-world data to develop algorithmic support tools to inform personalized, multi-modal patient care in near-real time. From deriving insight from complex data to tackling treatment artifacts we need to unlearn, Khozin shares his vision for improving precision and why data convergence at the point of care leaves him optimistic about a major inflection point for cancer treatment in the next 10 years.
Dr. Sean Khozin is on a mission to break down silos and improve access to quality cancer care for all. Khozin is a board-certified oncologist, physician scientist, data scientist and the CEO of ASCO’s CancerLinQ, a nonprofit health technology company focused on improving health outcomes for all patients with cancer.
On this episode of The Health Pulse, Khozin joins host Alex Maiersperger to discuss how his organization is democratizing access to the best cancer care by bringing real-world evidence based tools to the point of care. As Khozin explains, only about 5% of cancer patients can access clinical trials. This means in oncology, clinical trial data often lacks external validity because it represents highly selective patient populations. CancerLinQ helps close the gap using real-world data to develop algorithmic support tools to inform personalized, multi-modal patient care in near-real time. Khozin also discusses precision medicine and reflects on how far we’ve come and opportunities to improve, particularly in the area of health care delivery. He also shares his perspective on regulatory science as translational science.
From deriving insight from complex data to tackling treatment artifacts we need to unlearn, Khozin shares his vision for improving precision and why data convergence at the point of care leaves him optimistic about a major inflection point for cancer treatment in the next 10 years.
Transcript available here.
All presentations represent the opinions of the presenter and do not represent the position or the opinion of SAS.
On this episode of The Health Pulse, Khozin joins host Alex Maiersperger to discuss how his organization is democratizing access to the best cancer care by bringing real-world evidence based tools to the point of care. As Khozin explains, only about 5% of cancer patients can access clinical trials. This means in oncology, clinical trial data often lacks external validity because it represents highly selective patient populations. CancerLinQ helps close the gap using real-world data to develop algorithmic support tools to inform personalized, multi-modal patient care in near-real time. Khozin also discusses precision medicine and reflects on how far we’ve come and opportunities to improve, particularly in the area of health care delivery. He also shares his perspective on regulatory science as translational science.
From deriving insight from complex data to tackling treatment artifacts we need to unlearn, Khozin shares his vision for improving precision and why data convergence at the point of care leaves him optimistic about a major inflection point for cancer treatment in the next 10 years.
Transcript available here.
All presentations represent the opinions of the presenter and do not represent the position or the opinion of SAS.
